Molecular Partners (MOLN) Projected to Post Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) will likely be announcing its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 8:00 AM ET.

Molecular Partners Price Performance

Shares of NASDAQ:MOLN opened at $4.93 on Wednesday. The firm has a market capitalization of $199.07 million, a price-to-earnings ratio of -2.57 and a beta of 1.03. The business’s 50 day simple moving average is $4.47 and its 200-day simple moving average is $4.12. Molecular Partners has a 12 month low of $3.36 and a 12 month high of $5.36.

Analysts Set New Price Targets

Several brokerages recently issued reports on MOLN. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research report on Monday, December 22nd. JPMorgan Chase & Co. dropped their price target on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research report on Monday, December 8th. Finally, HC Wainwright began coverage on shares of Molecular Partners in a research report on Tuesday, January 27th. They issued a “buy” rating and a $13.00 price objective on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $9.58.

Hedge Funds Weigh In On Molecular Partners

A hedge fund recently bought a new stake in Molecular Partners stock. SmartHarvest Portfolios LLC acquired a new stake in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund acquired 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors and hedge funds.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.